Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.83 |
| ▸ | JAK3 | P52333 | 14/20 | 0.83 |
| ▸ | JAK1 | P23458 | 7/20 | 0.67 |
| ▸ | TYK2 | P29597 | 5/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.67 |
| ▸ | FLT3 | P36888 | 2/20 | 0.67 |
| ▸ | PLK4 | O00444 | 2/20 | 0.67 |
| ▸ | CIT | O14578 | 2/20 | 0.67 |
| ▸ | GAK | O14976 | 2/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.67 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.67 |
| ▸ | MARK3 | P27448 | 2/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.67 |
| ▸ | NEK3 | P51956 | 2/20 | 0.67 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.67 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.67 |
| ▸ | ULK3 | Q6PHR2 | 2/20 | 0.67 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 2/20 | 0.67 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376622 | 1.00 | JAK2 (0.83) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL8230689 | 0.93 | JAK2 (0.72) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4378171 | 0.91 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4383319 | 0.91 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4378180 | 0.91 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4374507 | 0.88 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4377065 | 0.88 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4375622 | 0.87 | JAK2 (0.64) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4375617 | 0.87 | JAK2 (0.64) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4378034 | 0.86 | JAK2 (0.95) | JAK2JAK3JAK1TYK2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.